Institution · Vertex Pharmaceuticals (United States)
Most cited papers from Vertex Pharmaceuticals (United States)
Vertex Pharmaceuticals (United States)
What are the most cited papers from Vertex Pharmaceuticals (United States)?
The most cited paper from Vertex Pharmaceuticals (United States) is "A global reference for human genetic variation" (Corresponding authors et al., 2015), with 20,444 citations. Next come "Analysis of protein-coding genetic variation in 60,706 humans" (10,439) and "The mutational constraint spectrum quantified from variation in 141,456 humans" (10,422).
Showing 50 of 59 papers. Every paper with more than 464 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | A global reference for human genetic variation Corresponding authors et al. · Nature | 29 Sep 2015 | 20,444 |
| 2 | Analysis of protein-coding genetic variation in 60,706 humans Monkol Lek et al. · Nature | Aug 2016 | 10,439 |
| 3 | The mutational constraint spectrum quantified from variation in 141,456 humans Konrad J. Karczewski et al. · Nature | 27 May 2020 | 10,422 |
| 4 | A reference panel of 64,976 haplotypes for genotype imputation Shane McCarthy et al. · Nature Genetics | 22 Aug 2016 | 3,318 |
| 5 | AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules David A. Pearlman, David Andrew Case, James W. Caldwell et al. · Computer Physics Communications | Sep 1995 | 3,156 |
| 6 | Identification of common genetic risk variants for autism spectrum disorder Jakob Grove et al. · Nature Genetics | 25 Feb 2019 | 2,721 |
| 7 | The Properties of Known Drugs. 1. Molecular Frameworks Guy W. Bemis, Mark A. Murcko · Journal of Medicinal Chemistry | 1996 | 2,604 |
| 8 | Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection Ira M. Jacobson et al. · New England Journal of Medicine | 22 Jun 2011 | 2,394 |
| 9 | Human ICE/CED-3 Protease Nomenclature Emad S. Alnemri, David J. Livingston, Donald W. Nicholson et al. · Cell | Oct 1996 | 2,392 |
| 10 | Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB Dongsheng Cai, Minsheng Yuan, Daniel Frantz et al. · Nature Medicine | 30 Jan 2005 | 2,245 |
| 11 | A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation Bonnie W. Ramsey, Jane Carolyn Davies, Noel Gerard McElvaney et al. · New England Journal of Medicine | 2 Nov 2011 | 2,213 |
| 12 | Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele Peter Gordon Middleton et al. · New England Journal of Medicine | 31 Oct 2019 | 2,211 |
| 13 | CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia Haydar Frangoul et al. · New England Journal of Medicine | 5 Dec 2020 | 1,969 |
| 14 | Reduced Apoptosis and Cytochrome c–Mediated Caspase Activation in Mice Lacking Caspase 9 Keisuke Kuida, Tarik F. Haydar, Chia‐Yi Kuan et al. · Cell | Aug 1998 | 1,663 |
| 15 | The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity Michael B. Yaffe, Katrin Rittinger, Stefano Volinia et al. · Cell | Dec 1997 | 1,653 |
| 16 | Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR Claire Elizabeth Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine | 17 May 2015 | 1,650 |
| 17 | Altered Cytokine Export and Apoptosis in Mice Deficient in Interleukin-1β Converting Enzyme Keisuke Kuida, Judith A. Lippke, George Ku et al. · Science | 31 Mar 1995 | 1,638 |
| 18 | Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial Harry G.M. Heijerman et al. · The Lancet | Nov 2019 | 1,420 |
| 19 | Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 Fredrick Van Goor et al. · Proceedings of the National Academy of Sciences | 21 Oct 2009 | 1,245 |
| 20 | Small molecules, big targets: drug discovery faces the protein–protein interaction challenge Duncan E. Scott, Andrew R. Bayly, Chris Abell et al. · Nature Reviews Drug Discovery | 6 Apr 2016 | 1,172 |
| 21 | Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection John G. McHutchison, Gregory T. Everson, Stuart C. Gordon et al. · New England Journal of Medicine | 29 Apr 2009 | 1,090 |
| 22 | Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection Christophe Hézode, Nicole Forestier, Geoffrey M Dusheiko et al. · New England Journal of Medicine | 29 Apr 2009 | 1,028 |
| 23 | Virtual screening—an overview W. Patrick Walters, Matthew T. Stahl, Mark A. Murcko · Drug Discovery Today | Apr 1998 | 1,009 |
| 24 | VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Elizabeth A. Harrington, David Bebbington, Jeffrey R. Moore et al. · Nature Medicine | 22 Feb 2004 | 965 |
| 25 | Discovering the anticancer potential of non-oncology drugs by systematic viability profiling Steven M. Corsello et al. · Nature Cancer | 20 Jan 2020 | 925 |
| 26 | The promise and peril of chemical probes C.H. Arrowsmith et al. · Nature Chemical Biology | 21 Jul 2015 | 864 |
| 27 | Structure and mechanism of interleukin-lβ converting enzyme Keith P. Wilson, Jo-Anne F. Black, John A. Thomson et al. · Nature | Jul 1994 | 849 |
| 28 | X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex James P Griffith, Joseph L. Kim, Eunice E Kim et al. · Cell | Aug 1995 | 839 |
| 29 | Biologically erodable microspheres as potential oral drug delivery systems Edith Mathiowitz, Jules S. Jacob, Yong S. Jong et al. · Nature | Mar 1997 | 826 |
| 30 | Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation Frank J. Accurso et al. · New England Journal of Medicine | 17 Nov 2010 | 807 |
| 31 | Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine | 3 Nov 2017 | 801 |
| 32 | The BioPAX community standard for pathway data sharing Emek Demir et al. · Nature Biotechnology | Sep 2010 | 782 |
| 33 | Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation Anubha Mahajan et al. · Nature Genetics | May 2022 | 774 |
| 34 | Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection Kenneth E. Sherman, Steven L. Flamm, Nezam H. Afdhal et al. · New England Journal of Medicine | 15 Sep 2011 | 748 |
| 35 | VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles D. Keating, Gautham Marigowda, Lucy D. Burr et al. · New England Journal of Medicine | 18 Oct 2018 | 742 |
| 36 | Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide J.L Kim, Kurt A. Morgenstern, Chao Lin et al. · Cell | Oct 1996 | 732 |
| 37 | Telaprevir for Previously Treated Chronic HCV Infection John G. McHutchison, Michael Peter Manns, Andrew J. Muir et al. · New England Journal of Medicine | 7 Apr 2010 | 721 |
| 38 | Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins Paul S. Charifson, Joseph J. Corkery, Mark A. Murcko et al. · Journal of Medicinal Chemistry | 25 Nov 1999 | 694 |
| 39 | Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Philip M. Reaper, Matthew R. Griffiths, Joanna M. Long et al. · Nature Chemical Biology | 13 Apr 2011 | 650 |
| 40 | Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene Patrick R. Sosnay et al. · Nature Genetics | 25 Aug 2013 | 640 |
| 41 | Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding Joseph L. Kim, Kurt A. Morgenstern, James P Griffith et al. · Structure | 1998 | 619 |
| 42 | Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir Christoph Sarrazin, Tara L. Kieffer, Doug J. Bartels et al. · Gastroenterology | 22 Feb 2007 | 618 |
| 43 | Quorum Sensing in Staphylococcus aureus Biofilms Jeremy M. Yarwood, Douglas J. Bartels, Esther M. Volper et al. · Journal of Bacteriology | 2 Mar 2004 | 601 |
| 44 | Alchemical free energy methods for drug discovery: progress and challenges John D. Chodera, David L. Mobley, Michael R. Shirts et al. · Current Opinion in Structural Biology | 24 Feb 2011 | 591 |
| 45 | Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome Vanessa S. Marsden, Liam J. O’Connor, Lorraine Ann O’Reilly et al. · Nature | 25 Sep 2002 | 587 |
| 46 | Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. Adrian J. Puren, Giamila Fantuzzi, Yun Gu et al. · Journal of Clinical Investigation | Feb 1998 | 553 |
| 47 | Enantioselective Catalytic Formation of Quaternary Stereogenic Centers Pier Giorgio Cozzi, Robert Hilgraf, Nicole Zimmermann · European Journal of Organic Chemistry | 29 Oct 2007 | 546 |
| 48 | Deuterium in drug discovery: progress, opportunities and challenges Rita Maria Concetta Di Martino, Brad D. Maxwell, Tracey Pirali · Nature Reviews Drug Discovery | 5 Jun 2023 | 530 |
| 49 | The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection Dario S. Zamboni, Koichi S. Kobayashi, Tiana Kohlsdorf et al. · Nature Immunology | 29 Jan 2006 | 523 |
| 50 | Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis Steven Mark Rowe, Cori L. Daines, Felix C. Ringshausen et al. · New England Journal of Medicine | 3 Nov 2017 | 522 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.